214 related articles for article (PubMed ID: 23318794)
21. In vivo resistance of a laboratory-selected Aspergillus fumigatus isolate to amphotericin B.
Manavathu EK; Cutright JL; Chandrasekar PH
Antimicrob Agents Chemother; 2005 Jan; 49(1):428-30. PubMed ID: 15616327
[TBL] [Abstract][Full Text] [Related]
22.
Seyedmousavi S; Mouton JW; Melchers WJG; Verweij PE
Antimicrob Agents Chemother; 2017 Jun; 61(6):. PubMed ID: 28416540
[TBL] [Abstract][Full Text] [Related]
23. Effects of amphotericin B on Aspergillus flavus clinical isolates with variable susceptibilities to the polyene in an experimental model of systemic aspergillosis.
Barchiesi F; Spreghini E; Sanguinetti M; Giannini D; Manso E; Castelli P; Girmenia C
J Antimicrob Chemother; 2013 Nov; 68(11):2587-91. PubMed ID: 23794598
[TBL] [Abstract][Full Text] [Related]
24. In-vitro testing of susceptibility to amphotericin B is a reliable predictor of clinical outcome in invasive aspergillosis.
Lass-Flörl C; Kofler G; Kropshofer G; Hermans J; Kreczy A; Dierich MP; Niederwieser D
J Antimicrob Chemother; 1998 Oct; 42(4):497-502. PubMed ID: 9818749
[TBL] [Abstract][Full Text] [Related]
25. Increased frequency of non-fumigatus Aspergillus species in amphotericin B- or triazole-pre-exposed cancer patients with positive cultures for aspergilli.
Lionakis MS; Lewis RE; Torres HA; Albert ND; Raad II; Kontoyiannis DP
Diagn Microbiol Infect Dis; 2005 May; 52(1):15-20. PubMed ID: 15878437
[TBL] [Abstract][Full Text] [Related]
26. Intrinsic in vitro susceptibility of primary clinical isolates of Aspergillus fumigatus, Aspergillus terreus, Aspergillus nidulans, Candida albicans and Candida lusitaniae against amphotericin B.
Singh J; Rimek D; Kappe R
Mycoses; 2006 Mar; 49(2):96-103. PubMed ID: 16466441
[TBL] [Abstract][Full Text] [Related]
27. Amphotericin B in vitro resistance is associated with fatal Aspergillus flavus infection.
Hadrich I; Makni F; Neji S; Cheikhrouhou F; Bellaaj H; Elloumi M; Ayadi A; Ranque S
Med Mycol; 2012 Nov; 50(8):829-34. PubMed ID: 22587728
[TBL] [Abstract][Full Text] [Related]
28. Epidemiology and outcome of infections due to Aspergillus terreus: 10-year single centre experience.
Lass-Flörl C; Griff K; Mayr A; Petzer A; Gastl G; Bonatti H; Freund M; Kropshofer G; Dierich MP; Nachbaur D
Br J Haematol; 2005 Oct; 131(2):201-7. PubMed ID: 16197450
[TBL] [Abstract][Full Text] [Related]
29. Amphotericin B resistance of Aspergillus terreus in a murine model of disseminated aspergillosis.
Dannaoui E; Borel E; Persat F; Piens MA; Picot S
J Med Microbiol; 2000 Jul; 49(7):601-606. PubMed ID: 10882084
[TBL] [Abstract][Full Text] [Related]
30. Emerging Role of Sphingolipids in Amphotericin B Drug Resistance.
Madaan K; Bari VK
Microb Drug Resist; 2023 Aug; 29(8):319-332. PubMed ID: 37327022
[TBL] [Abstract][Full Text] [Related]
31. Experimental murine aspergillosis. Comparison of amphotericin B and a new polyene antifungal drug, SCH 28191.
Graybill JR; Kaster SR
Am Rev Respir Dis; 1984 Feb; 129(2):292-5. PubMed ID: 6364905
[TBL] [Abstract][Full Text] [Related]
32. High-dose induction liposomal amphotericin B followed by de-escalation is effective in experimental Aspergillus terreus pneumonia.
Lewis RE; Albert NP; Liao G; Wang W; Prince RA; Kontoyiannis DP
J Antimicrob Chemother; 2013 May; 68(5):1148-51. PubMed ID: 23349440
[TBL] [Abstract][Full Text] [Related]
33. Evaluation of amphotericin B and micafungin combination against clinical isolates of Aspergillus species.
Nishi I; Sunada A; Toyokawa M; Asari S; Iwatani Y
J Chemother; 2011 Apr; 23(2):102-6. PubMed ID: 21571627
[TBL] [Abstract][Full Text] [Related]
34. Diversity of clinical isolates of Aspergillus terreus in antifungal susceptibilities, genotypes and virulence in Galleria mellonella model: Comparison between respiratory and ear isolates.
Won EJ; Choi MJ; Shin JH; Park YJ; Byun SA; Jung JS; Kim SH; Shin MG; Suh SP
PLoS One; 2017; 12(10):e0186086. PubMed ID: 29016668
[TBL] [Abstract][Full Text] [Related]
35. Efficacy of LY303366 against amphotericin B-susceptible and -resistant Aspergillus fumigatus in a murine model of invasive aspergillosis.
Verweij PE; Oakley KL; Morrissey J; Morrissey G; Denning DW
Antimicrob Agents Chemother; 1998 Apr; 42(4):873-8. PubMed ID: 9559799
[TBL] [Abstract][Full Text] [Related]
36. Itraconazole preexposure attenuates the efficacy of subsequent amphotericin B therapy in a murine model of acute invasive pulmonary aspergillosis.
Lewis RE; Prince RA; Chi J; Kontoyiannis DP
Antimicrob Agents Chemother; 2002 Oct; 46(10):3208-14. PubMed ID: 12234846
[TBL] [Abstract][Full Text] [Related]
37. Allicin enhances the oxidative damage effect of amphotericin B against Candida albicans.
An M; Shen H; Cao Y; Zhang J; Cai Y; Wang R; Jiang Y
Int J Antimicrob Agents; 2009 Mar; 33(3):258-63. PubMed ID: 19095412
[TBL] [Abstract][Full Text] [Related]
38.
Siopi M; Mouton JW; Pournaras S; Meletiadis J
Antimicrob Agents Chemother; 2019 Jun; 63(6):. PubMed ID: 30962332
[No Abstract] [Full Text] [Related]
39. Posaconazole enhances the activity of amphotericin B against Aspergillus hyphae in vitro.
Perkhofer S; Lugger H; Dierich MP; Lass-Flörl C
Antimicrob Agents Chemother; 2007 Feb; 51(2):791-3. PubMed ID: 17116665
[TBL] [Abstract][Full Text] [Related]
40. Molecular identification, phylogenetic analysis and antifungal susceptibility patterns of Aspergillusnidulans complex and Aspergillusterreus complex isolated from clinical specimens.
Mohamadnia A; Salehi Z; Namvar Z; Tabarsi P; Pourabdollah-Toutkaboni M; Rezaie S; Marjani M; Moniri A; Abtahian Z; Mahdaviani SA; Mortezaee V; Askari E; Sharifynia S
J Mycol Med; 2020 Sep; 30(3):101004. PubMed ID: 32534826
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
